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Sary Thirty-eight patients with advanced non-seminomatous germ cell tumours (NSGCTs) underwent
multiple surgical interventions (two in 33 patients, three in four patients, four in one patient) after cisplatin-
based chemotherapy. All patients had normal serum tumour markers but persistent radiographic masses. The
larger mass was routinely resected first. Fifteen patients (39%) had dissimilar histological findings at sequential
surgical procedures, 12 of whom demonstrated less favourable pathological features during the first operation
and three at the second. Patients who underwent both retroperitoneal lymph node dissection (RPLND) and
lung resection showed less favourable histological features in the retroperitoneum in nine cases and in the lung
in three cases. Eight of 16 patients (50%) without mature teratoma in their primary tumours showed complete
necrosis/fibrosis at all surgical interventions, whereas all patients whose primary tumour was classified as
malignant teratoma intermediate demonstrated mature teratoma at least at one anatomical site. As histology
of post-chemotherapy residual masses cannot be extrapolated from one anatomical site to another, patients
usually are properly managed by excision of all residual masses. In particular, in patients with necrosis/fibrosis
at lung resection omission of RPLND is not advised.
Cisplatin-based chemotherapy has dramatically improved the
prognosis of patients with metastatic non-seminomatous
germ cell tumours (NSGCTs). Patients with a low tumour
burden are cured by chemotherapy in a high degree. How-
ever, patients with large-volume metastatic disease often
achieve only a partial radiological remission. Residual masses
consist of either necrosis/fibrosis, differentiated (mature)
teratoma or viable undifferentiated tumour tissue. The nature
of persisting radiological abnormalities can only be deter-
mined by surgical excision.
Several investigators recommend surgical resection of all
post-chemotherapy residual masses if feasible (Donohue &
Rowland, 1984; Tait et al., 1984; Tiffany et al., 1986; Har-
ding et al., 1989; Toner et al., 1990; Qvist et al., 1991;
Kulkarni et al., 1991). However, as in some patients nothing
but complete necrosis/fibrosis is found in all surgically
removed specimens, the question arises of whether the
number of surgical interventions could be reduced in selected
patients. In this study, we analysed our experience with
multiple surgical interventions following cisplatin-based
chemotherapy of advanced NSGCTs. To determine the
necessity of multiple surgical procedures, the histological
findings at separate anatomical sites were compared.
diagnosis was made according to the British Testicular
Tumour Panel (Pugh, 1976) and World Health Organization
(WHO) classification (Mostofi & Sobin, 1977). The histology
of the primary tumour was classified as malignant teratoma
undifferentiated (WHO classification: embryonal carcinoma)
in 14 cases (37%), as malignant teratoma intermediate (WHO
classification: teratocarcinoma) consisting of embryonal car-
cinoma and mature teratoma in 15 cases (39%), as malignant
teratoma differentiated (WHO classification: mature tera-
toma) in two (5%), as malignant teratoma trophoblastic
(WHO classification: choriocarcinoma) in four (11%) and as
pure seminoma in one (3%). In the last case a considerable
elevation of serum tumour markers a-fetoprotein (AFP) and
human chorionic gonadotropin (HCG) indicated the presence
of non-seminomatous elements; moreover, a surgically
resected cerebral metastasis was classified as malignant tera-
toma intermediate. In eight further cases primary tumours
contained seminoma elements (combination tumours). In two
cases no histological diagnosis was obtained but very high
levels of HCG indicated the presence of metastatic NSGCT.
In one of these cases the tumour-bearing testicle was com-
pletely necrotic owing to torsion; in the other case no biopsy
was taken from the primary extragonadal tumour because of
a life-threatening trophoblastic teratoma syndrome (And-
reyev et al., 1993).
Patients and methods
Patient characteristics
From 1980 to 1993, 109 consecutive patients with NSGCTs
at Klinikum Grosshadern underwent surgery for removal of
residual masses after normalisation of serum tumour markers
with cisplatin-based chemotherapy. Thirty-eight patients
(35%) required two or more surgical interventions. Two of
these 38 patients had clinical stage III disease (supradia-
phragmatic lymph node involvement) and 36 presented with
stage IV disease (visceral metastases). Thirty-five patients had
tumours of testicular origin, whereas in three cases tumours
were extragonadal (retroperitoneal) in origin. Histological
Chemotherapy
None of the patients had undergone prior radiation. All
patients received first-line chemotherapy; patients who under-
went salvage chemotherapy for relapsing NSGCT were not
included in this study. Before 1984 chemotherapy consisted
of cisplatin, vinblastine and bleomycin in conventional doses
(Williams et al., 1987). From 1984 to 1993 patients were
mainly treated according to the ECBC protocol, including
etoposide, cisplatin, bleomycin and cyclophosphamide (Gerl
et al., 1993a,b). Few patients received chemotherapy accord-
ing to the PEB protocol (Williams et al., 1987). A mean
number of 5.6 cycles (range 4-14 cycles) of chemotherapy
was administered prior to surgery. Patients with undiffer-
entiated tumour resected at post-chemotherapy surgery
routinely underwent two cycles of cisplatin-ifosfamide-based
chemotherapy (Clemm et al., 1986).
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Surgery
Serum tumour markers HCG and AFP had normalised in all
patients who underwent post-chemotherapy surgical resec-
tion. All patients had residual masses at abdominal and/or
thoracic computerised tomographic (Ct) scans. The excision
of the larger mass was routiely undertaken first. In patients
with extended pulmonary and retroperitoneal tumour resid-
uals, thoracotomy usually preceded RPLND, as we regarded
Tabe I Order of post-chemotherapy surgical interventions and histological
findings
Patient Histology of Post-dhmotherapy Histoogy of










































































































































Mature teratoma%2 A. GERL et al.
Taie I (Conined)
Pati Histology of Post-chemotherapy Histology of
no. pn twW sugery metatasis
Sequential bilateral thoracotomies without other interventions
33 MiT Tboracotomy x 2 Necrosis x 2
34 MTU Thoracotomy x 2 Necrosis x 2
35a MTU Thoracotomy x 2 Mature teratoma
Ncrosis
36 MTI Thoracotomy x 2 Mature teratoma x 2
37 MTU Thoracotomy x 2 Undifferentiated tumour x 2






aPatients with differnt histology at sequential operations. MTU, malignant
teratomaundifferentiated; MTI,malgnantteratomaintemediate;MTD,malgnant
teratoma differentiated; MIT, malignant teratoma trophoblastc.
this sequence to be better tolerated by the patients. If
extended bilateral pulmonary residuals had to be resected,
sequential bilateral interventions using lateral incisions were
preferred instead of a sternotomy. Tberefore, few patients
with abdominal and thoracic residual mass underwent
more than two surgical procedures.
Retroperitoneal lymph node dissection (RPLND) was per-
formed in 32 patients, an unilateral thoracotomy for lung
resection in 16, bilateral thoracotoin in eight, hepatic
resection in five, neck dissection in four and inguinal lymph
node dissection in one. Six patients underwent resection of
m iastinal masses, two of them in association with a lung
resection. Twenty-five patients underwent sequential rsction
of residual abdominal and thoracic masses: in 14 cases
RPLND was the first surgial procedure, whereas in 11 cases
thoracotomy preceded RPLND. In summary, two surgical
procedures were performed in 33 patients, three in four
patients and four in one patient. The histologial response of
resected specimens was classifie as necrosis/fibrosis, differ-
entiated (mature) teratoma or undifferentiated tumour. For
all 38 patients, primary histology, the order of surgical
interventions and postchemotherapy histological findings are
summarised in Table I.
Follow-up
After resection of residual masses patients underwent follow-
up examinations at 3 month intervals during the first and
second year. In the third year patients were seen every 6
months and thereafter annually. Examinations included
physical examination, laboratory testing including serum
tumour markers, chest radiography and abdominal and
thoracic CT scans.
Rests
Histological examination of specimens from the first surgical
intervention after chemotherapy disclosed necrosis/fibrosis in
15 (39%), mature teratoma in 19 (50%) and undifferentiated
tumour in four cases (11/%). During the second post-
chemotherapy operation necrosis/fibrosis was identified in 22
patients (58%), differentiated teratoma in 15 (40%) and
undifferentiated tumour in one case (3%). The last patient
also had undifferentiated tumour in his specimen resected
during the first surgical intervention. During the third
intervention one patient had resected undifferentiated
tumour, while mature teratoma and necrosis were found at
the first and second procedures. In 12 of the 38 patients
(32%) necrosis/fibrosis was found in all surgically removed
specimens. Differentiated teratoma was identified in ten
patients (26%) at all operations.
Fifteen patients (39%) had dissimilar histological findings
at post-chemotherapy surgical procedures (Table I).
TAb U Distribution of histological features in specimens resected
post-chemotherapy at various anatomical sites
Anatomical No. (%) ofinterventions Undifferentiated
site Necrosis Mature teratoma tumour
Lung 22(61) 10(28) 4 (11)
Retroperitoneum 11 (34) 19 (59) 2 (6)
Liver 3 (60) 2 (40) 0 (0)
Mediastinum 4 (67) 2 (33) 0 (0)
Neck 2 (50) 2 (50) 0 (0)
higuen 0 (0) 1 (100) 0 (0)
Total 42 (49) 37 (44) 6 (7)
Undifferentiated tumour tissue is regarded as less favourable
than mature teratoma and the latter less favourable than
necrosis/fibrosis. Considering these criteria, in 12 cases less
favourable histological findings were identified at the first
surgical intervention and in three cases at the second oper-
ation. In 12 patients who underwent both RPLND and lung
resection a less favourable histology was found in the retro-
peritoneum in nine cases and in the lung in three cases. Of
nine patients who harboured necrosis/fibrosis at RPLND, in
eight cases necrosis/fibrosis was also identified at thor-
acotomy, and only one patient showed mature teratoma at
thoracic surgery. Conversely, of 17 patients who harboured
necrosis/fibrosis at thoracotomy, only eight also showed
necrosis/fibrosis at RPLND, while in eight cases mature
teratoma was identified, and in one patient undifferentiated
tumour.
Considering all 38 patients, complete necrosis was much
more frequently found at lung resection (61%) than at
RPLND (34%) (P = 0.03, chi-square test) (Table II). Con-
versely, mature teratoma was more frequently identified at
RPLND (59%) than at thoracotomy (28%) (P= 0.01, chi-
square test). Of the eight patients who underwent bilateral
thoracotomies for lung resection, necrosis/fibrosis,
differentiated teratoma and undifferentiated tumour were
identified at both surgical interventions in four, one and one
cases respectively. Two patients showed less favourable his-
tological findings at the first operation.
Of the 16 patients who had no mature teratoma in their
pnmary tumours, eight (50%) showed complete necrosis/
fibrosis at all post-chemotherapy surgical interventions. How-
ever, seven patients (44%) whose primary tumours did not
contain mature teratomatous elements demonstrated mature
teratoma at post-chemotherapy surgery: three in the retro-
peritoneum, two in the retroperitoneum and liver, one in the
retroperitoneum and lung and one only in the lung. In
contrast, all 15 patients whose pnmary tumours were
lasified as malignant teratoma intermediate showed mature
teratoma at post-chemotherapy surgery (P<0.00, Fisher's
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undifferentiated tumour. Differentiated teratoma was found
at one anatomical site in seven patients, at two sites in seven
patients and at three sites in one patient. In 12 of the 14.
cases differentiated teratoma was detected in the retro-
peritoneal space.
No major complications were observed after post-chemo-
therapy surgery, and there was no treatment-related mor-
tality. Thirty-three of the 38 patients (87%) are currently
alive, 25 with continuous no evidence of disease status and
three with stable residual masses which could not be resected
completely. Of the last three cases, one had residual masses
in the lung, the second in the lung and retroperitoneum and
the third in the lung and liver. Incomplete surgery had
disclosed mature teratoma in all three patients. Six patients
are alive after relapse, four disease-free and two with disease
at the beginning of salvage treatment too early to assess for
response (Table III). Two of these patients underwent repeat
surgery as sole salvage treatment, and histological examina-
tion revealed mature teratoma in one case and necrosis/
fibrosis in the other case. Median follow-up of surviving
patients is 84 months (range 5-146 months). Five patients
died, four from metastatic germ ce tumour (Table l).
One patient died from non-Hodgkin lymphoma; he had
shown mature teratoma in surgially resected specimens, and
only mature teratoma was found at post-mortem examma-
tion.
Cisplatin-based chemotherapy regmens lead to complete
remissions (CR) in 60-70% of patients with bulky stage H,
stage HI and IV NSGCTs. Surgical excision of residual
masses can augment the clnical CR rate by roughly 20%,
increasing the overall CR rate to between 80% and 90%
(Tiffany et al., 1986). Although no conclusion has been
reached about whether all patients should undergo excision
of post-chemotherapy residual masses (Levitt et al., 1985;
Donohue et al., 1987; Fossa et al., 1992), the majority of
reports recommend the excision ofall tumour residuals. Post-
chemotherapy surgery allows an accurate staging which helps
to define the need for further treatment (Fox et al., 1993) and
which also has prognostic implications. The majority of
investigators found that patients with complete necrosis/
fibrosis did better than those with mature teratoma and the
latter better than those with undfferentiated tumour in their
post-chemotherapy surgical specimens (Tait et al., 1984;
Gedler et al., 1989; Staehker et al., 1989, Jansen et al.,
1991; Mead et al., 1992; Hendry et al., 1993). However, two
reports could not confirm the prognostic relevance of his-
tological features at post-chemotherapy surgery (Harding et
al., 1989; Steyerberg et al., 1993). Another criterion which
appears to be associated with a favourable clinical outcome is
the completeness of surgical resection (Harding et al., 1989;
Jansen et al., 1991; Hendry et al., 1993; Steyerberg et al.,
1993).
Several investigators have found that post-chemotherapy
resected contain undifferentiated tumour in about
20% and mature teratoma and necrosis/fibrosis in roughly
40% and 40% respectively (Denaley et al., 1991; Jansen et
al., 1991; Mead et al., 1992; Steyerberg et al., 1993). In our
series undifferentiated tumour was found in only 7% of
resected tissue specms. This rate is lower than in most
other reports and may be a result of prolonged and
intensified treatment with a mean number of 5.6 cycles of
chemotherapy. A low rate ofundifferentiated tumour in post-
chemotherapy residuals was also reported by other inves-
tigators who treated their patients with a mean number of
5.2 chemotherapy cycles (Freiha et al., 1984), whereas a
higher rate of undifferentiated tumour was found in patients
treated with only three cycles of chemotherapy (Pizzocaro et
al., 1985).
Surgical resection of residual masses containing un-
differentiated tumour may be curative in some patients and
defines the need for firther treatment with chemotherapy
(Fox et al., 1993). Patients with differentiated teratoma in
tumour residuals may also benefit from post-chemotherapy
surgery, as mature teratoma may have the potential to grow
Table III Clinical outcome of patients with recurrent disease after sequential post-chemotherapy
surgery
Patient Sites Sites of Salwage Clinical
no. involved Surgery relapse treatnmnt outcome
4 Retroperitoneum RPLND Brain Surgery DOD
Liver Hepatotomy Radiation
Lung Lung Chemotherapy
7 Retroperitonewn RPLND Marker At start Too early
Lung Tboracotomy only to a
Neck
16 Retroperitoneum RPLND Brain Radiation NED
Lung Tboracotomy Bone Chemotherapy
Neck Neck dissection
Brain At start Too early
to assess
19 Retroperitoneum RPLND Brain Surgery DOD
Liver Hepatotomy Radiation
Mediastinum Tboracotomy Lung Chemotheapy
Lung
Neck
23 Lung Tboracotomy Lung Chemotherapy DOD
Retroperitoneum RPLND
24 Lung Tboracotomy Brain Surgery NED
Retroperitoneum RPLND Radiation
28 Lung Thoracotomy Lung Chemotherapy DOD
Retroperitoneum RPLND Liver
31 Lung Thoracotomy Lung Surgry NED
Retroperitoneun RPLND (mature teratoma)
Inguen Surgery
(mature teratoma)
35 Lung Thoracotomy x 2 Lung Surgery NED
(necrosi)
37 Lung Thoracotomy x 2 Lung Chemotherapy NED
Gingiva Surgery
DOD, dead of disease; NED, no evidence of disease.964 A. GERL et al.
(Logothetis et al., 1982), and in some cases it may be respon-
sible for late tumour recurrences (Roth et al., 1988; Gelder-
man et al., 1989). If, however, necrosis/fibrosis is found in all
resected specimens, probably no benefit is gained from sur-
gical interventions. Although morbidity of post-chemother-
apy surgery is tolerable, and mortality is low in specialised
centres, the question rises of whether the number of surgical
interventions could be reduced safely in selected patients.
Since radical RPLND leads to dry ejaculation in a con-
siderable proportion ofpatients, a case in point would be the
elimination of RPLND in patients with negative histological
findings at thoracotomy.
We compared the response to chemotherapy at various
anatomical sites and detected dissimilar histological findings
in 39% of patients. Other investigators described different
pathological features in 29%, 35% and 47% (Mandelbaum
et al., 1983; Tiffany et al., 1986; Qvist et al., 1991). Of our
patients who underwent resection of both lungs and
RPLND, 9 of 12 harboured the less favourable histological
features in the retroperitoneum. Similar observations were
made by two of the aforementioned investigators (Mandel-
baum et al., 1983; Tiffany et al., 1986); while the third report,
which included only 15 patients, could not confirm this
finding (Qvist et al., 1991). Our data demonstrate that
patients harbouring necrosis/fibrosis at RPLND have a high
chance of finding necrosis/fibrosis also at thoracotomy. Con-
versely, patients showing necrosis/fibrosis at thoracotomy
often do not demonstrate the same favourable histology at
RPLND.
It is of interest that patients who underwent resection of
both abdominal and thoracic residual masses demonstrated
more frequently mature teratoma than patients who required
post-chemotherapy surgery only at one anatomical site
(Donohue & Rowland, 1984). In agreement with other
reports (Donohue et al., 1987; Gelderman et al., 1988; Toner
et al., 1990; Qvist et al., 1991), we found that the lack of
mature teratoma in the primary tumour was associated with
a lower probability offinding differentiated teratoma at post-
chemotherapy surgery. However, 44% of these patients
showed mature teratoma, most often at the retroperitoneal
space. In a large series, 33% of patients whose primary
tumours did not contain mature teratomatous elements
demonstrated differentiated teratoma at post-chemotherapy
RPLND (Toner et al., 1990). Conversely, it is notable that all
patients of our series with a histological diagnosis of malig-
nant teratoma intermediate showed mature teratoma at post-
chemotherapy surgery, at least at one anatomical site. An
association between malignant teratoma intermediate in the
primary tumour and a high frequency of differentiated
teratoma resected at post-chemotherapy surgery has been
described by several investigators (Donohue et al., 1987;
Gelderman et al., 1988; Toner et al., 1990).
It is of note that in six patients relapses occurred in the
lungs after thoracotomy, in five of whom surgery had been
regarded as complete. However, in one patient only necrosis
was identified at repeat thoracotomy, and a further patient
relapsed only with mature teratoma underscoring the need
for histological confirmation in marker-negative recurrent
disease. Furthermore, it is of interest that four relapses
occurred in the brain either alone or in association with a
relapse at other sites. The central nervous system has been
recognised as a sanctuary site of relapse in chemotherapy-
treated germ cell tumours (Gerl et al., 1994).
In conclusion, histological findings in residual masses fol-
lowing chemotherapy for advanced NSGCTs cannot be
extrapolated from one anatomical site to another. Since no
reliable criteria exist to predict the precise nature of post-
chemotherapy residual masses, surgical excision ofall tumour
residuals is usually advised. As the retroperitoneal space
often harbours less favourable histological findings, elimina-
tion of RPLND in patients with necrosis/fibrosis at thor-
acotomy is discouraged. Conversely, close observation of
small continuously shrinking pulmonary residuals may be
justified in patients with necrosis/fibrosis at RPLND.
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